Chartwell Investment Partners, LLC Affimed N.V. Transaction History

Chartwell Investment Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	BUY	$1.96 - $3.32 $9,137 - $15,477	4,662 Added 3.66%	132,199 $272,000
Q2 2022 Aug 01, 2022	BUY	$2.27 - $4.86 $131,326 - $281,165	57,853 Added 83.02%	127,537 $353,000
Q1 2022 Apr 26, 2022	BUY	$3.69 - $5.65 $10,767 - $16,486	2,918 Added 4.37%	69,684 $304,000
Q4 2021 Feb 15, 2022	SELL	$5.37 - $7.07 $6,556 - $8,632	-1,221 Reduced 1.8%	66,766 $368,000
Q2 2021 Jul 19, 2021	BUY	$7.78 - $11.4 $4,761 - $6,976	612 Added 0.91%	67,987 $577,000
Q1 2021 May 03, 2021	SELL	$5.12 - $8.48 $18,534 - $30,697	-3,620 Reduced 5.1%	67,375 $533,000
Q4 2020 Feb 09, 2021	BUY	$3.16 - $7.03 $224,344 - $499,094	70,995 New	70,995 $413,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Chartwell Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Chartwell Investment Partners, LLC with notifications on news.